Symbols

ACIU

AC Immune·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

High Gross Profit Margin

Significant Net Income Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ACIU

Ac Immune Sa

A biotech company that develops therapeutic and diagnostic products for Alzheimer's disease and other neurodegenerative disorders

Industry

Biological Technology

Established Date

02/13/2003

Listing Date

09/23/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

172

Fiscal Year Ends

12-31

Website

www.acimmune.com

Security Type

Common stock

Office address

EPFL INNOVATION PARK, Building B, 1015 Lausanne, Switzerland

Business

Introduction

AC Immune SA was first incorporated in Basel on February 13, 2003 as a limited liability company and was later incorporated in June 2021 under the laws of the State of Delaware. AC Immune SA is a leading clinical-stage biopharmaceutical company dedicated to pioneering the field of precision medicine in neurodegenerative diseases. Leveraging two proprietary technology platforms, Supra Antigen and Morphomer, the company has built a comprehensive pipeline of first-in-class or best-in-class drug candidates covering multiple treatment models for both existing and emerging neurodegenerative diseases. The company is currently advancing 16 therapeutic and diagnostic programs, seven of which are undergoing clinical trials for five different types of misfolded pathological proteins associated with Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases.

Company Financials

EPS

ACIU has released its 2024 Q4 earnings. EPS was reported at -0.18, versus the expected -0.21471352695215, beating expectations. The chart below visualizes how ACIU has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ACIU has released its 2025 Q3 earnings report, with revenue of 1.18M, reflecting a YoY change of -96.09%, and net profit of -19.91M, showing a YoY change of -405.46%. The Sankey diagram below clearly presents ACIU's revenue sources and cost distribution.